2020 Fiscal Year Final Research Report
Detection of DNA sequence responsible for the interstitial lung disease specific for Japanese
| Project/Area Number |
18H02820
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Keywords | 薬剤性肺障害 / EGFR / EGFR-TKI / MUC4 |
|---|
| Outline of Final Research Achievements |
The aim of the current study is to identify a genetic factor responsible for the interstitial lung disease specific for Japanese. Recently, vulnerability of Japanese to interstitial lung diseases has been widely recognized. First, drug-induced interstitial lung disease occurs at a higher frequency in Japanese than people in other ethnic groups. Second, acute exacerbation is more frequently observed in the patients with interstitial pulmonary fibrosis. These conditions often occur in medical services, and hinders safe medical services. We decided to elucidate the genetic factors that cause interstitial lung diseases in Japanese, and thus help to contribute to a safer medical services. We compared the non-synonymous SNPs in patients and healthy people and identified the MUC4 gene as a candidate gene.
|
| Free Research Field |
呼吸器内科学
|
| Academic Significance and Societal Importance of the Research Achievements |
日本人には肺障害が高率に発症する．2004年，肺がん治療薬ゲフィチニブが上市された直後から肺障害が多発した．ゲフィチニブによる肺障害は海外ではど報告されていない．特発性肺線維症急性増悪も，ゲフィチニブ肺障害同様，日本で高頻度に発生し，同じ病理像を示す．我々は，日本人特有の単一遺伝因子が薬剤性肺障害および特発性肺線維症の原因という作業仮説を設定し原因遺伝子を追求することとした．
|
